Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Thura Win Htut, MBBS, MRCP, Donald P. Quick, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Somedeb Ball, MD, Ei Moe Phyu, MD, Nyein Htway Yu, MBBS, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Nicholas D'Cunha, MD, Sanjay Awasthi, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5550.

https://doi.org/10.1182/blood-2019-123156

Published: 2019

Journal Articles

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

My L Nguyen, PharmD, Catherine Burdalski, PharmD, BCOP, Syed Abbas Ali, MD, Lindsay Kohler, BS, PharmD Candidate, Steven Gilmore, PharmD, BCOP

Blood (2019) 134 (Supplement_1): 5811.

https://doi.org/10.1182/blood-2019-125391

Published: 2019

Journal Articles

Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Pamela Santana, Ricardo Saad, MSc, Adrielle Kolanian, Cyntia Fioratti, Marcela Junqueira, Tassia Decimoni, MSc

Blood (2019) 134 (Supplement_1): 3149.

https://doi.org/10.1182/blood-2019-131742

Published: 2019

Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Blood (2019) 134 (Supplement_1): 3152.

https://doi.org/10.1182/blood-2019-123560

Published: 2019

Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1866.

https://doi.org/10.1182/blood-2019-123483

Published: 2019

Journal Articles

Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Nimesh Adhikari, MD, Ei Moe Phyu, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 1873.

https://doi.org/10.1182/blood-2019-123164

Published: 2019

Journal Articles

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Kyaw Zin Thein, MDMBBS, Anita Sultan, MD, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Sanjay Awasthi, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD

Blood (2019) 134 (Supplement_1): 3485.

https://doi.org/10.1182/blood-2019-123145

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Thura Win Htut, MBBS, MRCP, Aung M Tun, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Ei Moe Phyu, MD, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 4771.

https://doi.org/10.1182/blood-2019-123169

Published: 2019

Journal Articles

Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis

Chutima Kunacheewa, MD, Lei Feng, MS, Elisabet E. Manasanch, MD, Qaiser Bashir, MBBS, Krina K. Patel, MDMSc, Rohtesh S. Mehta, MD, Gregory P. Kaufman, MD, Swaminathan P. Iyer, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Robert Z. Orlowski, MD, PhD, Muzaffar H. Qazilbash, MD, Hans C. Lee, MD

Blood (2019) 134 (Supplement_1): 3198.

https://doi.org/10.1182/blood-2019-130537

Published: 2019

Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Blood (2018) 132 (Supplement 1): LBA-2.

https://doi.org/10.1182/blood-2018-120737

Published: 2018

Journal Articles

Sickle Cell Subjects Have a Stronger and Faster Neurally Mediated Vasoconstriction Response to Cold Pain That Correlates with Anxiety Scores

Saranya Veluswamy, MD, Payal Shah, MS, Maha Khaleel, MD, Mammen Puliyel, MD MBBS, Wanwara Thuptimdang, MS, Patjanaporn Chalacheva, PhD, John Sunwoo, MS, Christopher Clement Denton, MD, Roberta Miyeko Kato, MD, Jon A Detterich, MD, John C Wood, MD PhD, Richard Sposto, PhD, Michael Khoo, PhD, Lonnie Zeltzer, MD, Thomas D. Coates, MD

Blood (2018) 132 (Supplement 1): 854.

https://doi.org/10.1182/blood-2018-99-113655

Published: 2018

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis

Muhammad Abu Zar, MD, Ahmad Kamal, MD, Ali Younas Khan, MD, Saad Ullah Malik, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Ceren Durer, MD, Seren Durer, MD, Insija Ilyas Selene, MBBS, Anum Qureshi, Jemin Aby Jose, MD, Hafiz Muhammad Fazeel, MD, Zunairah Shah, MBBS, Muhammad Adil Rehman, MBBS, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 3292.

https://doi.org/10.1182/blood-2018-99-110580

Published: 2018

Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Blood (2018) 132 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2018-99-115039

Published: 2018

Journal Articles

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Hervé Avet-Loiseau, MD PhD, Jesus F San-Miguel, MD PhD, Tineke Casneuf, PhD, Shinsuke Iida, MD PhD, Sagar Lonial, MD, Saad Z. Usmani, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Philippe Moreau, Torben Plesner, MD DSc, Katja Weisel, MD, Jon Ukropec, PhD, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, BS, Xiang Qin, Ming Qi, MD PhD, Christopher Chiu, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2018-99-113177

Published: 2018

Journal Articles

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Hervé Avet-Loiseau, MD PhD, Jianming He, PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Sourish Saha, Christopher Chiu, PhD, Sarah Cote, Annette Lam

Blood (2018) 132 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2018-99-113571

Published: 2018

Journal Articles

Treatment Efficacy in Relapsed/Refractory Multiple Myeloma: Outcomes Based on Racial Disparity

Hiba Jabbour, MD, Aula Rita Ramo, MD, Vijayalakshmi Donthireddy, MD

Blood (2018) 132 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2018-99-119181

Published: 2018

Journal Articles

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Nizar Bahlis, MD, Meletios A Dimopoulos, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, Maria Krevvata, PhD, Christopher Chiu, PhD, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD

Blood (2018) 132 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2018-99-112697

Published: 2018

NARROW

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Sickle Cell Subjects Have a Stronger and Faster Neurally Mediated Vasoconstriction Response to Cold Pain That Correlates with Anxiety Scores

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Treatment Efficacy in Relapsed/Refractory Multiple Myeloma: Outcomes Based on Racial Disparity

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only